Hematological Malignancies

Standard of care in pts with indolent lymphomas

• Still a role for watch & wait in asymptomatic pts • Wait for indication of treatment • Combined R-chemo standard; R-CHOP or R-Benda most often used • R-Benda with longer PFS and lower toxicity • No clear superiority of R-CHOP over R-CVP • R-chemo plus R-maintenance current best option in follicular, particularly in relapsed disease • High-dose chemo and ASCT in r&r or transformed pts • Perspectives: Bortezomib, Lenalidomide, Obinutuzumab (GA101), Ofatumumab, Temsirolimus, Ibrutinib, Idelalisib, ABT-199